Literature DB >> 29255238

Acute lymphoblastic leukaemia in 2017: Immunotherapy for ALL takes the world by storm.

David T Teachey1, Stephen P Hunger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29255238     DOI： 10.1038/nrclinonc.2017.176

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.

Authors:  Hagop Kantarjian; Anthony Stein; Nicola Gökbuget; Adele K Fielding; Andre C Schuh; Josep-Maria Ribera; Andrew Wei; Hervé Dombret; Robin Foà; Renato Bassan; Önder Arslan; Miguel A Sanz; Julie Bergeron; Fatih Demirkan; Ewa Lech-Maranda; Alessandro Rambaldi; Xavier Thomas; Heinz-August Horst; Monika Brüggemann; Wolfram Klapper; Brent L Wood; Alex Fleishman; Dirk Nagorsen; Christopher Holland; Zachary Zimmerman; Max S Topp
Journal:  N Engl J Med       Date:  2017-03-02       Impact factor: 91.245

2.  Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.

Authors:  Wendy Landier; Lindsey Hageman; Yanjun Chen; Nancy Kornegay; William E Evans; Bruce C Bostrom; Jacqueline Casillas; David S Dickens; Anne L Angiolillo; Glen Lew; Kelly W Maloney; Leo Mascarenhas; A Kim Ritchey; Amanda M Termuhlen; William L Carroll; Mary V Relling; F Lennie Wong; Smita Bhatia
Journal:  J Clin Oncol       Date:  2017-03-24       Impact factor: 44.544

3.  Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.

Authors:  Arend von Stackelberg; Franco Locatelli; Gerhard Zugmaier; Rupert Handgretinger; Tanya M Trippett; Carmelo Rizzari; Peter Bader; Maureen M O'Brien; Benoît Brethon; Deepa Bhojwani; Paul Gerhardt Schlegel; Arndt Borkhardt; Susan R Rheingold; Todd Michael Cooper; Christian M Zwaan; Phillip Barnette; Chiara Messina; Gérard Michel; Steven G DuBois; Kuolung Hu; Min Zhu; James A Whitlock; Lia Gore
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

4.  Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.

Authors:  Hagop M Kantarjian; Daniel J DeAngelo; Anjali S Advani; Matthias Stelljes; Partow Kebriaei; Ryan D Cassaday; Akil A Merchant; Naohito Fujishima; Toshiki Uchida; Maria Calbacho; Anna A Ejduk; Susan M O'Brien; Elias J Jabbour; Hui Zhang; Barbara J Sleight; Erik R Vandendries; David I Marks
Journal:  Lancet Haematol       Date:  2017-07-04       Impact factor: 18.959

5.  Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.

Authors:  Giovanni Martinelli; Nicolas Boissel; Patrice Chevallier; Oliver Ottmann; Nicola Gökbuget; Max S Topp; Adele K Fielding; Alessandro Rambaldi; Ellen K Ritchie; Cristina Papayannidis; Lulu Ren Sterling; Jonathan Benjamin; Anthony Stein
Journal:  J Clin Oncol       Date:  2017-03-29       Impact factor: 44.544

6.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

Authors:  Hagop M Kantarjian; Daniel J DeAngelo; Matthias Stelljes; Giovanni Martinelli; Michaela Liedtke; Wendy Stock; Nicola Gökbuget; Susan O'Brien; Kongming Wang; Tao Wang; M Luisa Paccagnella; Barbara Sleight; Erik Vandendries; Anjali S Advani
Journal:  N Engl J Med       Date:  2016-06-12       Impact factor: 91.245

7.  Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Authors:  David T Teachey; Simon F Lacey; Pamela A Shaw; J Joseph Melenhorst; Shannon L Maude; Noelle Frey; Edward Pequignot; Vanessa E Gonzalez; Fang Chen; Jeffrey Finklestein; David M Barrett; Scott L Weiss; Julie C Fitzgerald; Robert A Berg; Richard Aplenc; Colleen Callahan; Susan R Rheingold; Zhaohui Zheng; Stefan Rose-John; Jason C White; Farzana Nazimuddin; Gerald Wertheim; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  Cancer Discov       Date:  2016-04-13       Impact factor: 39.397

8.  Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells.

Authors:  Waseem Qasim; Hong Zhan; Sujith Samarasinghe; Stuart Adams; Persis Amrolia; Sian Stafford; Katie Butler; Christine Rivat; Gary Wright; Kathy Somana; Sara Ghorashian; Danielle Pinner; Gul Ahsan; Kimberly Gilmour; Giovanna Lucchini; Sarah Inglott; William Mifsud; Robert Chiesa; Karl S Peggs; Lucas Chan; Farzin Farzeneh; Adrian J Thrasher; Ajay Vora; Martin Pule; Paul Veys
Journal:  Sci Transl Med       Date:  2017-01-25       Impact factor: 17.956

9.  The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.

Authors:  Yu Liu; John Easton; Ying Shao; Jamie Maciaszek; Zhaoming Wang; Mark R Wilkinson; Kelly McCastlain; Michael Edmonson; Stanley B Pounds; Lei Shi; Xin Zhou; Xiaotu Ma; Edgar Sioson; Yongjin Li; Michael Rusch; Pankaj Gupta; Deqing Pei; Cheng Cheng; Malcolm A Smith; Jaime Guidry Auvil; Daniela S Gerhard; Mary V Relling; Naomi J Winick; Andrew J Carroll; Nyla A Heerema; Elizabeth Raetz; Meenakshi Devidas; Cheryl L Willman; Richard C Harvey; William L Carroll; Kimberly P Dunsmore; Stuart S Winter; Brent L Wood; Brian P Sorrentino; James R Downing; Mignon L Loh; Stephen P Hunger; Jinghui Zhang; Charles G Mullighan
Journal:  Nat Genet       Date:  2017-07-03       Impact factor: 38.330
  9 in total
  10 in total

1.  CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.

Authors:  Vinodh Pillai; Kavitha Muralidharan; Wenzhao Meng; Asen Bagashev; Derek A Oldridge; Jaclyn Rosenthal; John Van Arnam; Jos J Melenhorst; Diwakar Mohan; Amanda M DiNofia; Minjie Luo; Sindhu Cherian; Jonathan R Fromm; Gerald Wertheim; Andrei Thomas-Tikhonenko; Michele Paessler; Carl H June; Eline T Luning Prak; Vijay G Bhoj; Stephan A Grupp; Shannon L Maude; Susan R Rheingold
Journal:  Blood Adv       Date:  2019-11-26

2.  Microrandomized trials for promoting engagement in mobile health data collection: Adolescent/young adult oral chemotherapy adherence as an example.

Authors:  Shuang Li; Alexandra M Psihogios; Elise R McKelvey; Annisa Ahmed; Mashfiqui Rabbi; Susan Murphy
Journal:  Curr Opin Syst Biol       Date:  2020-07-07

Review 3.  Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia.

Authors:  David T Teachey; Ching-Hon Pui
Journal:  Lancet Oncol       Date:  2019-03       Impact factor: 54.433

Review 4.  Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.

Authors:  Allison Barz Leahy; Caitlin W Elgarten; Stephan A Grupp; Shannon L Maude; David T Teachey
Journal:  Expert Rev Anticancer Ther       Date:  2018-10       Impact factor: 3.627

Review 5.  Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.

Authors:  David Porter; Noelle Frey; Patricia A Wood; Yanqiu Weng; Stephan A Grupp
Journal:  J Hematol Oncol       Date:  2018-03-02       Impact factor: 17.388

Review 6.  The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer.

Authors:  Adviti Naik; Arta Monir Monjazeb; Julie Decock
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

7.  First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach.

Authors:  Teilo H Schaller; David J Snyder; Ivan Spasojevic; Patrick C Gedeon; Luis Sanchez-Perez; John H Sampson
Journal:  J Immunother Cancer       Date:  2020-04       Impact factor: 13.751

8.  Targeting loss of heterozygosity for cancer-specific immunotherapy.

Authors:  Michael S Hwang; Brian J Mog; Jacqueline Douglass; Alexander H Pearlman; Emily Han-Chung Hsiue; Suman Paul; Sarah R DiNapoli; Maximilian F Konig; Drew M Pardoll; Sandra B Gabelli; Chetan Bettegowda; Nickolas Papadopoulos; Bert Vogelstein; Shibin Zhou; Kenneth W Kinzler
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-23       Impact factor: 12.779

9.  Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.

Authors:  Yoshihiro Gocho; Jingjing Liu; Jianzhong Hu; Wentao Yang; Neekesh V Dharia; Jingliao Zhang; Hao Shi; Guoqing Du; August John; Ting-Nien Lin; Jeremy Hunt; Xin Huang; Bensheng Ju; Lauren Rowland; Lei Shi; Dylan Maxwell; Brandon Smart; Kristine R Crews; Wenjian Yang; Kohei Hagiwara; Yingchi Zhang; Kathryn Roberts; Hong Wang; Elias Jabbour; Wendy Stock; Bartholomew Eisfelder; Elisabeth Paietta; Scott Newman; Giovanni Roti; Mark Litzow; John Easton; Jinghui Zhang; Junmin Peng; Hongbo Chi; Stanley Pounds; Mary V Relling; Hiroto Inaba; Xiaofan Zhu; Steven Kornblau; Ching-Hon Pui; Marina Konopleva; David Teachey; Charles G Mullighan; Kimberly Stegmaier; William E Evans; Jiyang Yu; Jun J Yang
Journal:  Nat Cancer       Date:  2021-01-21

Review 10.  Biological basis for novel mesothelioma therapies.

Authors:  Joanna Obacz; Henry Yung; Marie Shamseddin; Emily Linnane; Xiewen Liu; Arsalan A Azad; Doris M Rassl; David Fairen-Jimenez; Robert C Rintoul; Marko Z Nikolić; Stefan J Marciniak
Journal:  Br J Cancer       Date:  2021-07-05       Impact factor: 9.075
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.